Valuation: Precision Therapeutics Inc

Market Cap 140M 124M 116M 106M 200M 13.46B 201M 1.41B 545M 6.88B 526M 514M 22.08B P/E 2026 *
-6.94x
P/E 2027 * -110x
Enterprise Value 140M 124M 116M 106M 200M 13.46B 201M 1.41B 545M 6.88B 526M 514M 22.08B EV / Sales 2026 *
2.32x
EV / Sales 2027 * 0.32x
Free-Float
94.04%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision Therapeutics Inc

Manager TitleAgeSince
Chief Executive Officer 57 2026-02-08
Director of Finance/CFO - 2026-04-15
President - 2026-03-31
Director TitleAgeSince
Director/Board Member 66 2020-02-18
Chairman 78 2026-02-08
Director/Board Member 60 2020-07-08
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-8.33% - - 140M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.96%-0.59%+52.63%+128.54% 43.39B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2026 *2027 *
Net sales 60.4M 53.67M 50.09M 45.65M 86.1M 5.81B 86.9M 606M 235M 2.97B 227M 222M 9.53B 431M 383M 358M 326M 615M 41.46B 621M 4.33B 1.68B 21.2B 1.62B 1.58B 68.03B
Net income -41.4M -36.78M -34.33M -31.29M -59.02M -3.98B -59.57M -415M -161M -2.03B -155M -152M -6.53B -4.5M -4M -3.73M -3.4M -6.41M -433M -6.47M -45.16M -17.5M -221M -16.9M -16.53M -710M
Net Debt - -
Logo Precision Therapeutics Inc
Axe Compute Inc. is a virtual neocloud AI infrastructure platform. The Company provides customers with access to graphics processing unit (GPU) compute capacity for artificial intelligence (AI) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. It also operates a digital asset treasury focused on the Aethir token (ATH), the native utility token of the Aethir network. Its segments include Compute Services and Treasury Management and Drug Discovery Services. Its Drug Discovery Services segment provides services that include the application of AI using its proprietary biobank of tumor samples, as well as creation of proprietary 3D culture models used in drug development. The Company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two offerings: Axe Compute Access and Axe Compute Build.
Employees
-